CO2023003420A2 - Nuevos compuestos que tienen actividad inhibitoria sobre el receptor de prostaglandina e2 y usos de los mismos - Google Patents

Nuevos compuestos que tienen actividad inhibitoria sobre el receptor de prostaglandina e2 y usos de los mismos

Info

Publication number
CO2023003420A2
CO2023003420A2 CONC2023/0003420A CO2023003420A CO2023003420A2 CO 2023003420 A2 CO2023003420 A2 CO 2023003420A2 CO 2023003420 A CO2023003420 A CO 2023003420A CO 2023003420 A2 CO2023003420 A2 CO 2023003420A2
Authority
CO
Colombia
Prior art keywords
prostaglandin
receptor
inhibitory activity
new compounds
stereoisomer
Prior art date
Application number
CONC2023/0003420A
Other languages
English (en)
Inventor
Sang Kyun Lim
Yeri Lee
Donggeon Kim
Soo Bong Han
Chang Soo Yun
Hyun Jin Kim
Joo Youn Lee
Hyuk Lee
Sikwang Seong
Original Assignee
Korea Res Inst Chemical Tech
Kanaph Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chemical Tech, Kanaph Therapeutics Inc filed Critical Korea Res Inst Chemical Tech
Publication of CO2023003420A2 publication Critical patent/CO2023003420A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a un nuevo compuesto que tiene actividad inhibidora sobre el receptor de prostaglandina E2 y sus usos, y proporciona un compuesto representado por la fórmula I, un solvato, un estereoisómero o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende y un método para usarlo.
CONC2023/0003420A 2020-08-21 2023-03-21 Nuevos compuestos que tienen actividad inhibitoria sobre el receptor de prostaglandina e2 y usos de los mismos CO2023003420A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200105545 2020-08-21
PCT/KR2021/011143 WO2022039563A1 (en) 2020-08-21 2021-08-20 Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof

Publications (1)

Publication Number Publication Date
CO2023003420A2 true CO2023003420A2 (es) 2023-04-17

Family

ID=80322868

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0003420A CO2023003420A2 (es) 2020-08-21 2023-03-21 Nuevos compuestos que tienen actividad inhibitoria sobre el receptor de prostaglandina e2 y usos de los mismos

Country Status (14)

Country Link
US (1) US20230365582A1 (es)
EP (1) EP4200291A1 (es)
JP (1) JP2023537909A (es)
KR (1) KR20220023730A (es)
CN (1) CN116529238A (es)
AU (1) AU2021327622B2 (es)
BR (1) BR112023002626A2 (es)
CA (1) CA3191456A1 (es)
CL (1) CL2023000339A1 (es)
CO (1) CO2023003420A2 (es)
IL (1) IL300774A (es)
MX (1) MX2023002068A (es)
TW (1) TW202211917A (es)
WO (1) WO2022039563A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158221A1 (ko) * 2022-02-15 2023-08-24 주식회사 카나프테라퓨틱스 프로스타글란딘 e2 수용체에 대한 저해 활성을 갖는 신규 화합물 및 항암제를 포함하는 암 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526095A1 (en) * 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
CN104364239B (zh) * 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
JO3581B1 (ar) * 2014-10-29 2020-07-05 Lilly Co Eli مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics

Also Published As

Publication number Publication date
MX2023002068A (es) 2023-03-17
AU2021327622A1 (en) 2023-03-02
KR20220023730A (ko) 2022-03-02
CL2023000339A1 (es) 2023-08-18
CA3191456A1 (en) 2022-02-24
EP4200291A1 (en) 2023-06-28
WO2022039563A1 (en) 2022-02-24
TW202211917A (zh) 2022-04-01
CN116529238A (zh) 2023-08-01
AU2021327622B2 (en) 2024-03-07
BR112023002626A2 (pt) 2023-04-04
IL300774A (en) 2023-04-01
US20230365582A1 (en) 2023-11-16
JP2023537909A (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR109561A1 (es) Compuestos modulares de receptores tipo toll
UY32490A (es) Inhibidores de beta-secretasa
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CL2021000196A1 (es) Método de tratamiento de la epilepsia
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CO2023003420A2 (es) Nuevos compuestos que tienen actividad inhibitoria sobre el receptor de prostaglandina e2 y usos de los mismos
CO2022008719A2 (es) Compuestos para modular la actividad de fxr y usos de los mismos
UY37941A (es) Derivados de bencimidazol y sus usos
UY36124A (es) Derivados de carboxamida
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
UY36123A (es) Derivados de carboxamida
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead